Exome sequencing detection of two untranslated GFPT1 mutations in a family with limb-girdle myasthenia

The term ‘limb‐girdle myasthenia’ (LGM) was first used to describe three siblings with proximal limb weakness without oculobulbar involvement, but with EMG decrement and responsiveness to anticholinesterase medication. We report here that exome sequencing in the proband of this family revealed sever...

Full description

Saved in:
Bibliographic Details
Published inClinical genetics Vol. 85; no. 2; pp. 166 - 171
Main Authors Maselli, R.A., Arredondo, J., Nguyen, J., Lara, M., Ng, F., Ngo, M., Pham, J.M., Yi, Q., Stajich, J.M., McDonald, K., Hauser, M.A., Wollmann, R.L.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.02.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The term ‘limb‐girdle myasthenia’ (LGM) was first used to describe three siblings with proximal limb weakness without oculobulbar involvement, but with EMG decrement and responsiveness to anticholinesterase medication. We report here that exome sequencing in the proband of this family revealed several sequence variations in genes linked to proximal limb weakness. However, the only mutations that cosegregated with disease were an intronic IVS7‐8A>G mutation and the previously reported 3′‐UTR c.*22C>A mutation in GFPT1, a gene linked to LGM. A minigene assay showed that IVS7‐8A>G activates an alternative splice acceptor that results in retention of the last seven nucleotides of intron 7 and a frameshift leading to a termination codon 13 nucleotides downstream from the new splice site. An anconeus muscle biopsy revealed mild reduction of the axon terminal size and postsynaptic fold simplification. The amplitudes of miniature endplate potentials and quantal release were also diminished. The DNA of the mildly affected father of the proband showed only the intronic mutation along with sequence variations in other genes potentially relevant to LGM. Thus, this study performed in the family originally described with LGM showed two GFPT1 untranslated mutations, which may cause disease by reducing GFPT1 expression and ultimately impairing protein glycosylation.
Bibliography:NIH - No. 5R01NS049117-03
The Myasthenia Gravis Foundation of California
Appendix S1. Supplementary exome methods.Table S1.Single nucleotide variants.
ArticleID:CGE12118
istex:AC74DDA6A812F3CBD559C68A979468AD160F4644
The Muscular Dystrophy Association - No. MDA 4090; No. MDA 186447
ark:/67375/WNG-ZRB8ST96-J
These authors contributed equally to this study.
Nothing to declare.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Case Study-2
ObjectType-Feature-4
ObjectType-Report-1
ObjectType-Article-3
ISSN:0009-9163
1399-0004
DOI:10.1111/cge.12118